Macrophage migration inhibitory factor (MIF) plasma concentration in critically ill COVID-19 patients: a prospective observational study
Zitieren Sie bitte immer diese URN: urn:nbn:de:bvb:20-opus-228967
- Mortality in critically ill coronavirus disease 2019 (COVID-19) patients is high and pharmacological treatment strategies remain limited. Early-stage predictive biomarkers are needed to identify patients with a high risk of severe clinical courses and to stratify treatment strategies. Macrophage migration inhibitory factor (MIF) was previously described as a potential predictor for the outcome of critically ill patients and for acute respiratory distress syndrome (ARDS), a hallmark of severe COVID-19 disease. This prospective observationalMortality in critically ill coronavirus disease 2019 (COVID-19) patients is high and pharmacological treatment strategies remain limited. Early-stage predictive biomarkers are needed to identify patients with a high risk of severe clinical courses and to stratify treatment strategies. Macrophage migration inhibitory factor (MIF) was previously described as a potential predictor for the outcome of critically ill patients and for acute respiratory distress syndrome (ARDS), a hallmark of severe COVID-19 disease. This prospective observational study evaluates the predictive potential of MIF for the clinical outcome after severe COVID-19 infection. Plasma MIF concentrations were measured in 36 mechanically ventilated COVID-19 patients over three days after intensive care unit (ICU) admission. Increased compared to decreased MIF was significantly associated with aggravated organ function and a significantly lower 28-day survival (sequential organ failure assessment (SOFA) score; 8.2 ± 4.5 to 14.3 ± 3, p = 0.009 vs. 8.9 ± 1.9 to 12 ± 2, p = 0.296; survival: 56% vs. 93%; p = 0.003). Arterial hypertension was the predominant comorbidity in 85% of patients with increasing MIF concentrations (vs. decreasing MIF: 39%; p = 0.015). Without reaching significance, more patients with decreasing MIF were able to improve their ARDS status (p = 0.142). The identified association between an early MIF response, aggravation of organ function and 28-day survival may open future perspectives for biomarker-based diagnostic approaches for ICU management of COVID-19 patients.…
Autor(en): | Christian Bleilevens, Josefin Soppert, Adrian Hoffmann, Thomas Breuer, Jürgen Bernhagen, Lukas Martin, Lara Stiehler, Gernot Marx, Michael Dreher, Christian Stoppe, Tim-Philipp Simon |
---|---|
URN: | urn:nbn:de:bvb:20-opus-228967 |
Dokumentart: | Artikel / Aufsatz in einer Zeitschrift |
Institute der Universität: | Medizinische Fakultät / Klinik und Poliklinik für Anästhesiologie (ab 2004) |
Sprache der Veröffentlichung: | Englisch |
Titel des übergeordneten Werkes / der Zeitschrift (Englisch): | Diagnostics |
ISSN: | 2075-4418 |
Erscheinungsjahr: | 2021 |
Band / Jahrgang: | 11 |
Heft / Ausgabe: | 2 |
Aufsatznummer: | 332 |
Originalveröffentlichung / Quelle: | Diagnostics (2021) 11:2, 332. https://doi.org/10.3390/diagnostics11020332 |
DOI: | https://doi.org/10.3390/diagnostics11020332 |
Allgemeine fachliche Zuordnung (DDC-Klassifikation): | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Freie Schlagwort(e): | COVID-19; Horowitz Quotient; ICU treatment; Macrophage Migration Inhibitory Factor (MIF); SOFA Score; acute respiratory distress syndrome (ARDS) |
Datum der Freischaltung: | 29.08.2022 |
Datum der Erstveröffentlichung: | 17.02.2021 |
Lizenz (Deutsch): | CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International |